JAK-3 selective inhibitors (Advinus)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameJAK-3 selective inhibitors (Advinus)
Drug Alias NameRA-1 (Advinus Therapeutics)small molecule therapeutics (Advinus)RA-2
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK3
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEurofins Advinus Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEurofins Advinus Ltd
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A